Page 5 - Accelerated Approval Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

After another insightful conference this year, these are some of the key legal deal trends to expect from the health care and life sciences industries in 2023.

Sarah Silbiger/Getty Images, FILE(WASHINGTON) -- A congressional investigation into the Food and Drug Administration's review process for an Alzheimer's treatment found that the agency "deviated" from its standard procedures to approve the Aduhelm drug with inconsistent data. Aduhelm is notable for being the first drug in recent years approved to treat the underlying cause of Alzheimer's, a disease with no known cure that is characterized by progressive dementia that affects more than six million Americans, according to the Alzheimer's Association. The joint 18-mo...

The Food and Drug Administration's review process for an Alzheimer's treatment found that the agency "deviated" from its standard procedures to approve the Aduhelm drug.

Significant Necrosis Demonstrated in Invasive Ductal and Lobular Cancers, Which are Normally Resistant to Chemotherapy. Significant Necrosis from a Single...

Cui bono is Latin for "Who benefits?" It's the sister phrase of "sequi pecuniam/follow the money" and the orphan of "plebes/the people." All roads used to lead to Rome. Today, they lead to chosen industry. There are many sayings about...